1,470 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Cerity Partners LLC

Cerity Partners LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,470 shares of the medical research company’s stock, valued at approximately $348,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV increased its position in Charles River Laboratories International by 21.5% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock worth $78,000 after buying an additional 58 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Charles River Laboratories International by 5.7% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock worth $266,000 after buying an additional 61 shares in the last quarter. Advisor Partners II LLC increased its position in Charles River Laboratories International by 2.7% during the third quarter. Advisor Partners II LLC now owns 2,393 shares of the medical research company’s stock worth $469,000 after buying an additional 63 shares in the last quarter. M&T Bank Corp grew its position in shares of Charles River Laboratories International by 3.3% in the third quarter. M&T Bank Corp now owns 2,076 shares of the medical research company’s stock valued at $407,000 after purchasing an additional 66 shares during the period. Finally, Parkside Financial Bank & Trust grew its position in shares of Charles River Laboratories International by 10.8% in the third quarter. Parkside Financial Bank & Trust now owns 761 shares of the medical research company’s stock valued at $149,000 after purchasing an additional 74 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 0.5 %

Shares of CRL opened at $229.03 on Friday. The stock’s 50-day moving average is $253.48 and its two-hundred day moving average is $222.64. The stock has a market cap of $11.80 billion, a PE ratio of 24.87, a P/E/G ratio of 1.88 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the previous year, the firm posted $2.98 earnings per share. The company’s revenue was down 7.9% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now directly owns 13,550 shares in the company, valued at approximately $3,437,635. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on CRL. UBS Group lifted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Argus boosted their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Evercore ISI boosted their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).